FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Stem Cells Dev / Autologous and Allogeneic Equine Mesenchymal Stem Cells Exhi...
Stem cells and development2017; 26(7); 503-511; doi: 10.1089/scd.2016.0266

Autologous and Allogeneic Equine Mesenchymal Stem Cells Exhibit Equivalent Immunomodulatory Properties In Vitro.

Abstract: The use of allogeneic bone marrow-derived mesenchymal stem cells (BMDMSCs) may provide an effective alternative to autologous BMDMSCs for treatment of equine musculoskeletal injuries. However, concerns have been raised regarding the potential safety and effectiveness of allogeneic BMDMSCs. We conducted studies to assess the immunological properties of equine allogeneic BMDMSCs compared with those of autologous BMDMSCs. For assessment of inherent immunogenicity, the relative ability of allogeneic and autologous BMDMSCs to stimulate spontaneous proliferation of equine lymphocytes was compared. The immunosuppressive activity of the two cell types was evaluated by adding autologous or allogeneic BMDMSCs to activated lymphocytes and assessing suppression of lymphocyte proliferation and IFNγ production. Fifty-six allogeneic and 12 autologous combinations were evaluated. Studies were also done to elucidate mechanisms by which equine mesenchymal stem cells (MSCs) suppress lymphocyte function. Potential mechanisms evaluated included production of prostaglandin E (PGE), nitric oxide, transforming growth factor-beta, and indoleamine 2,3-dioxygenase. We found that autologous and allogeneic BMDMSCs both induced mild but equivalent levels of spontaneous lymphocyte activation in vitro. In in vitro assays assessing the ability of BMDMSCs to suppress activated lymphocytes, both allogeneic and autologous BMDMSCs suppressed T cell proliferation and IFNγ production to an equal degree. The primary mechanism of equine BMDMSC suppression of T cells was mediated by PGE. We concluded that allogeneic and autologous BMDMSCs are equivalent in terms of their immunomodulatory properties, and stimulated peripheral blood mononuclear cells appear to trigger the immunosuppressive properties of MSCs. Therefore, both cell types appear to have equal potency in modulating inflammatory processes related to acute or chronic musculoskeletal injuries in the horse.
Get Full Text
Publication Date: 2017-01-12 PubMed ID: 27958776DOI: 10.1089/scd.2016.0266Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper analyses the inflammatory responses of equine mesenchymal stem cells, both allogeneic and autologous types, in relation to the treatment of musculoskeletal injuries in horses. Results show that both types of stem cells exhibit equal response and effectiveness in treating horse injuries, debunking previous concerns on the safety and efficacy of allogeneic stem cells.

Introduction and Objective

  • The research aimed to discern the immunological properties of equine bone marrow-derived mesenchymal stem cells (BMDMSCs), specifically comparing allogeneic (from a different individual of the same species) and autologous (from the same individual) BMDMSCs.
  • The goal was to ascertain whether allogeneic BMDMSCs could be a viable alternative to autologous ones for treating equine musculoskeletal injuries.

Methodology

  • Tested the cells’ inherent immunogenicity, that is, their ability to stimulate spontaneous expansion of equine lymphocytes (white blood cells).
  • Analyzed the immunosuppressive activity of both allogeneic and autologous BMDMSCs by introducing them to activated lymphocytes and measuring the suppression of lymphocyte proliferation and IFNγ (a protein associated with immune response) production.
  • Explored the mechanisms of how mesenchymal stem cells (MSCs) suppress lymphocyte function, focusing on the production of prostaglandin E (PGE), nitric oxide, transforming growth factor-beta, and indoleamine 2,3-dioxygenase.

Results and Findings

  • The results showed that both autologous and allogeneic BMDMSCs induced mild but equivalent levels of spontaneous lymphocyte activation.
  • Both allogeneic and autologous BMDMSCs also suppressed T cell proliferation and IFNγ production equivalently in vitro assays.
  • The primary mechanism for BMDMSC suppression of T cells was found to be through PGE.

Conclusion and Implications

  • It was concluded that allogeneic and autologous BMDMSCs have equivalent immunomodulatory properties, indicating that allogeneic BMDMSCs could be a safe and effective alternative for treating musculoskeletal injuries in horses.
  • This suggests that allogeneic and autologous BMDMSCs have equal potential in modulating inflammatory processes related to acute or chronic musculoskeletal injuries in horses.

Cite This Article

APA
Colbath AC, Dow SW, Phillips JN, McIlwraith CW, Goodrich LR. (2017). Autologous and Allogeneic Equine Mesenchymal Stem Cells Exhibit Equivalent Immunomodulatory Properties In Vitro. Stem Cells Dev, 26(7), 503-511. https://doi.org/10.1089/scd.2016.0266

Publication

Stem cells and development
ISSN: 1557-8534
NlmUniqueID: 101197107
Country: United States
Language: English
Volume: 26
Issue: 7
Pages: 503-511

Researcher Affiliations

Colbath, Aimée C
  • 1 Orthopaedic Research Center, Colorado State University , Fort Collins, Colorado.
Dow, Steven W
  • 2 Clinical Sciences, Colorado State University , Fort Collins, Colorado.
Phillips, Jennifer N
  • 1 Orthopaedic Research Center, Colorado State University , Fort Collins, Colorado.
McIlwraith, C Wayne
  • 1 Orthopaedic Research Center, Colorado State University , Fort Collins, Colorado.
Goodrich, Laurie R
  • 1 Orthopaedic Research Center, Colorado State University , Fort Collins, Colorado.
  • 2 Clinical Sciences, Colorado State University , Fort Collins, Colorado.

MeSH Terms

  • Autoantigens / immunology
  • Bone Marrow Cells / cytology
  • Bone Marrow Cells / immunology
  • Cell Proliferation / physiology
  • Cells, Cultured
  • Humans
  • Leukocytes, Mononuclear / immunology
  • Lymphocyte Activation / physiology
  • Lymphokines / immunology
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / immunology
  • T-Lymphocytes / immunology

Citations

This article has been cited 27 times.
  1. Pezzanite LM, Timkovich AE, Sikes KJ, Chow L, Hendrickson DA, Becker JR, Webster A, Santangelo KS, Dow S. Erythrocyte removal from bone marrow aspirate concentrate improves efficacy as intra-articular cellular therapy in a rodent osteoarthritis model.. Ann Transl Med 2023 Jun 30;11(9):311.
    doi: 10.21037/atm-22-4256pubmed: 37404993google scholar: lookup
  2. Mayet A, Zablotski Y, Roth SP, Brehm W, Troillet A. Systematic review and meta-analysis of positive long-term effects after intra-articular administration of orthobiologic therapeutics in horses with naturally occurring osteoarthritis.. Front Vet Sci 2023;10:1125695.
    doi: 10.3389/fvets.2023.1125695pubmed: 36908512google scholar: lookup
  3. Niebergall-Roth E, Frank NY, Ganss C, Frank MH, Kluth MA. Skin-Derived ABCB5(+) Mesenchymal Stem Cells for High-Medical-Need Inflammatory Diseases: From Discovery to Entering Clinical Routine.. Int J Mol Sci 2022 Dec 21;24(1).
    doi: 10.3390/ijms24010066pubmed: 36613507google scholar: lookup
  4. Khandelwal V, Sharma T, Gupta S, Singh S, Sharma MK, Parashar D, Kashyap VK. Stem cell therapy: a novel approach against emerging and re-emerging viral infections with special reference to SARS-CoV-2.. Mol Biol Rep 2023 Mar;50(3):2663-2683.
    doi: 10.1007/s11033-022-07957-2pubmed: 36536185google scholar: lookup
  5. Cequier A, Vázquez FJ, Romero A, Vitoria A, Bernad E, García-Martínez M, Gascón I, Barrachina L, Rodellar C. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility.. Front Vet Sci 2022;9:957153.
    doi: 10.3389/fvets.2022.957153pubmed: 36337202google scholar: lookup
  6. Kearney CM, Khatab S, van Buul GM, Plomp SGM, Korthagen NM, Labberté MC, Goodrich LR, Kisiday JD, Van Weeren PR, van Osch GJVM, Brama PAJ. Treatment Effects of Intra-Articular Allogenic Mesenchymal Stem Cell Secretome in an Equine Model of Joint Inflammation.. Front Vet Sci 2022;9:907616.
    doi: 10.3389/fvets.2022.907616pubmed: 35812845google scholar: lookup
  7. Cequier A, Romero A, Vázquez FJ, Vitoria A, Bernad E, Fuente S, Zaragoza P, Rodellar C, Barrachina L. Equine Mesenchymal Stem Cells Influence the Proliferative Response of Lymphocytes: Effect of Inflammation, Differentiation and MHC-Compatibility.. Animals (Basel) 2022 Apr 11;12(8).
    doi: 10.3390/ani12080984pubmed: 35454231google scholar: lookup
  8. Uberti B, Plaza A, Henríquez C. Pre-conditioning Strategies for Mesenchymal Stromal/Stem Cells in Inflammatory Conditions of Livestock Species.. Front Vet Sci 2022;9:806069.
    doi: 10.3389/fvets.2022.806069pubmed: 35372550google scholar: lookup
  9. Depuydt E, Broeckx SY, Chiers K, Patruno M, Da Dalt L, Duchateau L, Saunders J, Pille F, Martens A, Van Hecke L, Spaas JH. Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries.. Front Vet Sci 2021;8:789293.
    doi: 10.3389/fvets.2021.789293pubmed: 35281431google scholar: lookup
  10. Estrada McDermott J, Pezzanite L, Goodrich L, Santangelo K, Chow L, Dow S, Wheat W. Role of Innate Immunity in Initiation and Progression of Osteoarthritis, with Emphasis on Horses.. Animals (Basel) 2021 Nov 13;11(11).
    doi: 10.3390/ani11113247pubmed: 34827979google scholar: lookup
  11. Aldrich ED, Cui X, Murphy CA, Lim KS, Hooper GJ, McIlwraith CW, Woodfield TBF. Allogeneic mesenchymal stromal cells for cartilage regeneration: A review of in vitro evaluation, clinical experience, and translational opportunities.. Stem Cells Transl Med 2021 Nov;10(11):1500-1515.
    doi: 10.1002/sctm.20-0552pubmed: 34387402google scholar: lookup
  12. Zayed M, Adair S, Dhar M. Effects of Normal Synovial Fluid and Interferon Gamma on Chondrogenic Capability and Immunomodulatory Potential Respectively on Equine Mesenchymal Stem Cells.. Int J Mol Sci 2021 Jun 15;22(12).
    doi: 10.3390/ijms22126391pubmed: 34203758google scholar: lookup
  13. Kamm JL, Riley CB, Parlane N, Gee EK, McIlwraith CW. Interactions Between Allogeneic Mesenchymal Stromal Cells and the Recipient Immune System: A Comparative Review With Relevance to Equine Outcomes.. Front Vet Sci 2020;7:617647.
    doi: 10.3389/fvets.2020.617647pubmed: 33521090google scholar: lookup
  14. Caffi V, Espinosa G, Gajardo G, Morales N, Durán MC, Uberti B, Morán G, Plaza A, Henríquez C. Pre-conditioning of Equine Bone Marrow-Derived Mesenchymal Stromal Cells Increases Their Immunomodulatory Capacity.. Front Vet Sci 2020;7:318.
    doi: 10.3389/fvets.2020.00318pubmed: 32656251google scholar: lookup
  15. Mund SJK, Kawamura E, Awang-Junaidi AH, Campbell J, Wobeser B, MacPhee DJ, Honaramooz A, Barber S. Homing and Engraftment of Intravenously Administered Equine Cord Blood-Derived Multipotent Mesenchymal Stromal Cells to Surgically Created Cutaneous Wound in Horses: A Pilot Project.. Cells 2020 May 8;9(5).
    doi: 10.3390/cells9051162pubmed: 32397125google scholar: lookup
  16. MacDonald ES, Barrett JG. The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses.. Front Vet Sci 2019;6:507.
    doi: 10.3389/fvets.2019.00507pubmed: 32039250google scholar: lookup
  17. Gugjoo MB, Hussain S, Amarpal, Shah RA, Dhama K. Mesenchymal Stem Cell-Mediated Immuno-Modulatory and Anti- Inflammatory Mechanisms in Immune and Allergic Disorders.. Recent Pat Inflamm Allergy Drug Discov 2020;14(1):3-14.
    doi: 10.2174/1872213X14666200130100236pubmed: 32000656google scholar: lookup
  18. Colbath AC, Dow SW, Hopkins LS, Phillips JN, McIlwraith CW, Goodrich LR. Single and repeated intra-articular injections in the tarsocrural joint with allogeneic and autologous equine bone marrow-derived mesenchymal stem cells are safe, but did not reduce acute inflammation in an experimental interleukin-1β model of synovitis.. Equine Vet J 2020 Jul;52(4):601-612.
    doi: 10.1111/evj.13222pubmed: 31821594google scholar: lookup
  19. Kamm JL, Parlane NA, Riley CB, Gee EK, Dittmer KE, McIlwraith CW. Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression.. PLoS One 2019;14(11):e0225161.
    doi: 10.1371/journal.pone.0225161pubmed: 31747418google scholar: lookup
  20. Magri C, Schramme M, Febre M, Cauvin E, Labadie F, Saulnier N, François I, Lechartier A, Aebischer D, Moncelet AS, Maddens S. Comparison of efficacy and safety of single versus repeated intra-articular injection of allogeneic neonatal mesenchymal stem cells for treatment of osteoarthritis of the metacarpophalangeal/metatarsophalangeal joint in horses: A clinical pilot study.. PLoS One 2019;14(8):e0221317.
    doi: 10.1371/journal.pone.0221317pubmed: 31465445google scholar: lookup
  21. Gugjoo MB, Fazili MR, Gayas MA, Ahmad RA, Dhama K. Animal mesenchymal stem cell research in cartilage regenerative medicine - a review.. Vet Q 2019 Dec;39(1):95-120.
    doi: 10.1080/01652176.2019.1643051pubmed: 31291836google scholar: lookup
  22. Hillmann A, Paebst F, Brehm W, Piehler D, Schubert S, Tárnok A, Burk J. A novel direct co-culture assay analyzed by multicolor flow cytometry reveals context- and cell type-specific immunomodulatory effects of equine mesenchymal stromal cells.. PLoS One 2019;14(6):e0218949.
    doi: 10.1371/journal.pone.0218949pubmed: 31247035google scholar: lookup
  23. Calle A, López-Martín S, Monguió-Tortajada M, Borràs FE, Yáñez-Mó M, Ramírez MÁ. Bovine endometrial MSC: mesenchymal to epithelial transition during luteolysis and tropism to implantation niche for immunomodulation.. Stem Cell Res Ther 2019 Jan 11;10(1):23.
    doi: 10.1186/s13287-018-1129-1pubmed: 30635057google scholar: lookup
  24. Broeckx SY, Seys B, Suls M, Vandenberghe A, Mariën T, Adriaensen E, Declercq J, Van Hecke L, Braun G, Hellmann K, Spaas JH. Equine Allogeneic Chondrogenic Induced Mesenchymal Stem Cells Are an Effective Treatment for Degenerative Joint Disease in Horses.. Stem Cells Dev 2019 Mar 15;28(6):410-422.
    doi: 10.1089/scd.2018.0061pubmed: 30623737google scholar: lookup
  25. Ball AN, Phillips JN, McIlwraith CW, Kawcak CE, Samulski RJ, Goodrich LR. Genetic modification of scAAV-equine-BMP-2 transduced bone-marrow-derived mesenchymal stem cells before and after cryopreservation: An "off-the-shelf" option for fracture repair.. J Orthop Res 2019 Jun;37(6):1310-1317.
    doi: 10.1002/jor.24209pubmed: 30578639google scholar: lookup
  26. Piuzzi NS, Dominici M, Long M, Pascual-Garrido C, Rodeo S, Huard J, Guicheux J, McFarland R, Goodrich LR, Maddens S, Robey PG, Bauer TW, Barrett J, Barry F, Karli D, Chu CR, Weiss DJ, Martin I, Jorgensen C, Muschler GF. Proceedings of the signature series symposium "cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies-promise, facts and fantasy," international society for cellular therapies, montreal, canada, may 2, 2018.. Cytotherapy 2018 Nov;20(11):1381-1400.
    doi: 10.1016/j.jcyt.2018.09.001pubmed: 30316562google scholar: lookup
  27. Bogers SH. Cell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Know.. Front Vet Sci 2018;5:70.
    doi: 10.3389/fvets.2018.00070pubmed: 29713634google scholar: lookup
Subscribe to our newsletter
Join 99,105 horse owners like you who receive our email updates on horse health and nutrition.